← All indications
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Subtype terms (1)
More specific conditions that are subtypes of Multiple Myeloma in the MeSH hierarchy.
- Leukemia, Plasma Cell
50 drugs (36 approved, 14 experimental)
Drugs by status
Approved for this indication (29)
- carfilzomib
- thalidomide
- melphalan
- Motixafortide
- belantamab mafodotin
- idecabtagene vicleucel
- ixazomib
- ciltacabtagene autoleucel
- bortezomib
- 4-hydroxycyclophosphamide
- Talquetamab
- doxorubicin
- plerixafor
- selinexor
- vorinostat
- elotuzumab
- cyclophosphamide
- pomalidomide
- teclistamab
- zoledronic acid
- capivasertib
- dexamethasone
- lenalidomide
- daratumumab
- carmustine
- linvoseltamab
- Isatuximab
- panobinostat
- Elranatamab
Phase 4 trials (29)
- apixaban
- famotidine
- pentaisomaltose
- montelukast
- urea
- dasatinib
- Filgrastim
- acetaminophen
- allogeneic hematopoietic stem cells
- sargramostim
- pneumococcal 13-valent conjugate vaccine
- methylprednisolone
- levofloxacin
- thiotepa
- prednisone
- epirubicin
- Anti-thymocyte Globulin (Rabbit)
- mitoxantrone
- fludarabine
- fenofibrate
- palifermin
- stem cells
- loratadine
- tigecycline
- allogeneic adipose derived mesenchymal stem cell
- autologous mononuclear stem cell
- tocilizumab
- pirarubicin
- busulfan
Phase 3 trials (114)
- venetoclax
- allogeneic bone marrow
- darbepoetin beta
- epoetin
- somatropin
- tazobactam
- COVID-19 Vaccine, Adjuvanted
- qls32015
- hyaluronidase (human recombinant)
- lomustine
- naltrexone
- abbv-383
- ibandronate
- bendamustine
- calcium
- carvedilol
- wobe-mugos e
- diphenhydramine
- pembrolizumab
- ketamine
- denosumab
- equecabtagene autoleucel
- cc-95266
- amifostine
- mycophenolate
- vincristine
- oblimersen sodium
- amitriptyline
- nivolumab
- sirolimus
- +84 more
Phase 2 trials (442)
- cemiplimab
- leflunomide
- isb 1442
- apo010
- Imetelstat
- enzastaurin
- alvocidib
- basiliximab
- c144-ls
- ccs1477
- encorafenib
- oricar-017
- allogeneic cord blood
- vitamin c
- sar439459
- pegaspargase
- oxaliplatin
- vatalanib
- quercetin
- everolimus
- rituximab
- magrolimab
- minocycline
- gpc-100
- erlotinib
- descartes 11
- colesevelam
- tacedinaline
- veliparib
- ricolinostat
- +412 more
Phase 1 trials (333)
- pyroxamide
- cmv-specific t-cells
- th1/tc1 rapa cell
- tj011133
- vp301
- stro-001
- mik665
- ryz101
- vsv-hifnbeta-nis
- fhnd6091
- cmv-mva
- cd70 car-t cells
- ab308
- ioversol
- ckd-581
- ro7425781
- ws-cart-cs1
- sgn-cd48a
- psoralen
- medi7247
- il-7
- ave-1642
- huanglian-jie-du-tang
- bebt-908
- tetanus-cmv fusion peptide vaccine
- biw-8962
- rn1101
- krn7000 loaded dendritic cells
- svn53-67/m57-klh peptide vaccine
- okt10-b10
- +303 more
Other trials (45)
- lithium
- dapsone
- valganciclovir
- clofibrinic acid
- bismuth
- foscarnet
- f-18-psma-1007
- enoxaparin
- interleukin-6
- granisetron
- utaa17
- 89zr-bevacizumab
- 3,3',5,5'-tetraiodothyroacetic acid
- glucose
- florbetaben F-18
- procaine benzylpenicillin
- act-001 car-nk cell
- ritonavir
- platelets
- car-cld18 t cells
- umbilical cord mesenchymal stem cells
- fluconazole
- ct0590 car t cells
- red blood cells
- gpc3 car-t cell
- cd38 car-t cells
- calcium phosphate
- ct0594cp
- cd8 depleted donor lymphocyte
- clodronate
- +15 more
Organizations
Organization Involved with Phase 4 Indications (38)
- Emory University
- Columbia University
- University of Nice Sophia Antipolis
- Sanofi
- People's Liberation Army of China
- Central South University
- Peking University
- Harvard University
- Belarusian State Medical University
- Somerset Hematology Oncology
- Fujian Medical University
- University of Baghdad
- University of Florida
- Shandong Provincial Hospital
- Sun Yat-Sen University
- Harbin Medical University
- Vifor Inc.
- PETHEMA Foundation
- Biovitrum AB
- Minsk State Clinical Hospital No 9
- Soochow University
- Second Military Medical University
- Amgen
- Johnson and Johnson
- Jiao Tong University
- Swedish Orphan Biovitrum
- University of Maryland
- Capital Medical University
- Zhejiang University
- Osakidetza
- +8 more
Organization Involved with Phase 3 Indications (251)
- University of Bordeaux
- University of Arizona
- University of Tampere
- Nordic Myeloma Study Group
- University of Rochester
- University of Ottawa
- Case Western Reserve University
- Hospital Doce de Octubre Madrid
- University of Valencia
- University of Montreal
- University of Manitoba
- Intergroupe Francophone du Myelome
- Central Hospital of Kanta-Hame
- University of Bonn
- University of Helsinki
- Utrecht University
- University of Burgundy
- University of Stavanger
- Baylor University
- Barts & The London NHS Trust
- The University of Texas, Dallas
- HOVON - Dutch Haemato-Oncology Association
- University of Turku
- University of Utah
- Mayo Clinic
- University of Western Brittany
- University of Poitiers
- CH BAYONNE
- Laphal
- Genta
- +221 more
Organization Involved with Phase 2 Indications (340)
- University of Southern California
- Innate Pharma
- Diverse Biotech
- Titan Pharmaceuticals
- Piramal
- AstraZeneca
- University of Seville
- Chonnam National University
- inVentiv
- Vivolux AB
- Situs Cancer Research Center
- Bayer
- Vita-Salute University of Milano. Italy
- Luzerner Kantonsspital
- Kyowa Hakko Kirin
- Astex Pharmaceuticals, Inc.
- Myeloma UK
- Chroma Therapeutics
- University of Kansas
- Parke-Davis
- Kosin University
- Merck KGaA
- Criterium, Inc.
- KCAS Bio
- Accelovance
- Boston University
- Biotest Pharmaceuticals
- Monash University
- Christian Medical College, Vellore, India
- Our Lady of Mercy Medical Center
- +310 more
Organization Involved with Phase 1 Indications (124)
- New Mexico Cancer Care Alliance
- Sorrento Therapeutics, Inc.
- Reliable Cancer Therapies
- Hebei University
- Cedars-Sinai Medical Center
- bluebird bio
- Henan University of Traditional Chinese Medicine
- Fundación para la Investigación Biomédica del Hospital 12 de Octubre
- The Alfred Hospital
- Actinium Pharmaceuticals
- Gadeta B.V.
- Genus Oncology, LLC
- Applied Molecular Evolution
- Cellerant Therapeutics
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Phylogeny
- Technical University of Dresden
- The Spectrum Health Group
- La Jolla Pharmaceutical Company
- Fortis Therapeutics, Inc.
- MedImmune
- Allogene Therapeutics
- Cancer Research Institute
- Patrys Ltd.
- OncoEthix
- Cougar Biotechnology
- Theorem Clinical Research
- iCell Gene Therapeutics
- JW Pharmaceutical
- Gracell Biotechnology Ltd.
- +94 more
Organization Involved with Other Experimental Indications (10)